|Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies|
|Written by Sarah Jane Tribble and Sydney Lupkin | KHN|
|Tuesday, 17 January 2017 19:03|
More than 30 years ago, Congress overwhelmingly passed a landmark health bill aimed at motivating pharmaceutical companies to develop new drugs for people whose rare diseases had been ignored.
By the drugmakers' calculations, the markets for such diseases weren't big enough to bother with.
But lucrative financial incentives created by the Orphan Drug Act signed into law by President Ronald Reagan in 1983 succeeded far beyond anyone's expectations. More than 200 companies have brought almost 450 "orphan drugs" to market since the law took effect.
|Last Updated on Monday, 06 February 2017 19:22|
Website design, development, and hosting provided by